公开(公告)号：EP3482760B1

公开(公告)日：2021-11-10

申请号：EP17824314.3

申请日：2017-07-06

发明人： YOSHIDA, Takao ,  SHOYAMA, Akiko ,  TAKANO, Hirotsugu

IPC分类号： A61K31/353 ,  A61K45/06 ,  A61P35/00 ,  A61P43/00

公开(公告)号：EP3355875B1

公开(公告)日：2021-09-29

申请号：EP16782161.0

申请日：2016-09-30

发明人： VENKATARAMAN, Sriram ,  TUMAS, Daniel ,  TANAKA, Kohei ,  YASUHIRO, Tomoko ,  YOSHIZAWA, Toshio

IPC分类号： A61K31/122 ,  A61K31/351 ,  A61K31/4748 ,  A61K31/522 ,  A61K31/675 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395

公开(公告)号：EP3447045B1

公开(公告)日：2021-03-03

申请号：EP17786060.8

申请日：2017-04-21

发明人： YASHIRO, Kentaro ,  KATO, Masashi ,  SAITO, Tetsuji ,  OKADA, Takuya ,  WAKAMATSU, Daisuke ,  DAVENPORT, Adam James ,  STIMSON, Christopher Charles

IPC分类号： C07C275/32 ,  C07C271/30 ,  C07D239/26 ,  C07D309/04 ,  C07D307/52 ,  C07D277/28 ,  C07D261/08 ,  C07D241/12 ,  C07D213/74 ,  C07D213/64 ,  C07D213/40 ,  C07D209/14 ,  A61K31/505 ,  A61K31/4965 ,  A61K31/4545 ,  A61K31/4045 ,  A61K31/426 ,  A61K31/351 ,  A61K31/341 ,  A61K31/44 ,  A61P13/10

公开(公告)号：EP3702357A1

公开(公告)日：2020-09-02

申请号：EP20170445.9

申请日：2015-12-09

申请人： ONO Pharmaceutical Co., Ltd.

发明人： TANAKA, Motoyuki ,  KONDO, Takashi ,  HIROOKA, Yasuo ,  NISHIYAMA, Taihei ,  HIRAMATSU, Atsushi ,  KODA, Tomoyuki ,  KOUYAMA, Sho

IPC分类号： C07D471/04 ,  A61K31/444 ,  A61P7/02 ,  A61P43/00

摘要： A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.

公开(公告)号：EP3695839A1

公开(公告)日：2020-08-19

申请号：EP18866576.4

申请日：2018-10-12

申请人： ONO Pharmaceutical Co., Ltd. ,  Kyoto Prefectural Public University Corporation

发明人： TAKAYAMA, Koichi ,  YAMADA, Tadaaki ,  YASUHIRO, Tomoko ,  TANAKA, Kohei

IPC分类号： A61K31/4709 ,  A61K31/506 ,  A61P35/00 ,  A61P43/00 ,  C07D401/14

摘要： The present invention addresses the problem of finding an effective method for treating solid cancers and providing a pharmaceutical product therefor. The present invention provides a therapeutic agent for solid cancers, which contains N-{5-[(6, 7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2, 5- dioxo-1-phenyl-1, 2, 5, 6, 7, 8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt as an active ingredient, and which is characterized by being administered in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination of the present invention exerts a strong antitumor effect, and is therefore useful for treatment of solid cancers.

公开(公告)号：EP3693013A1

公开(公告)日：2020-08-12

申请号：EP18865322.4

申请日：2018-10-05

申请人： Ono Pharmaceutical Co., Ltd.

发明人： SHIBAYAMA, Shiro ,  TEZUKA, Tomoya

IPC分类号： A61K39/395 ,  A61P37/06 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C12N15/13

摘要： The present invention addresses the problem of providing a novel medical agent for prevention of auto-immune diseases, inhibition of symptom progression thereof, inhibition of recurrence thereof, or treatment thereof. As a result of conducting extensive studies, the inventors of the present invention have focused attention on PD-1/CD19 bispecific antibody as a substance with the potentiality of solving the problem, and have achieved the present invention. The PD-1/CD19 bispecific antibody according to the present invention exhibits growth-inhibitory action and immunoglobulin production inhibitory action against activated B cells, and also has inhibitory action against production of cytokine from memory T cells.

公开(公告)号：EP3632898A1

公开(公告)日：2020-04-08

申请号：EP18805980.2

申请日：2018-05-21

申请人： ONO Pharmaceutical Co., Ltd.

发明人： ASADA, Masaki ,  TANI, Kousuke ,  HIGUCHI, Satonori

IPC分类号： C07D209/08 ,  A61K31/427 ,  A61P37/00 ,  A61P43/00 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12

摘要： To provide a drug including a compound having an antagonistic activity with respect to EP 4 receptor in preventing and/or treating the disease caused by activation of an EP 4 receptor as an active ingredient. A compound represented by the general formula (I):

(wherein in the formula, all the symbols have the same meanings as those described in the description), or a pharmaceutically acceptable salt thereof is useful as a medicament component having an EP 4 receptor antagonistic activity, in preventing and/or treating the disease caused by activation of an EP 4 receptor.

公开(公告)号：EP3112368B1

公开(公告)日：2020-02-12

申请号：EP16176735.5

申请日：2011-05-30

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： YAMAMOTO, Shingo ,  YOSHIZAWA, Toshio

IPC分类号： C07D473/34 ,  A61K31/522 ,  A61P7/02 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06 ,  A61P43/00

公开(公告)号：EP3585789A1

公开(公告)日：2020-01-01

申请号：EP18710223.1

申请日：2018-02-23

申请人： Gilead Sciences, Inc. ,  Ono Pharmaceutical Co., Ltd.

发明人： LEE, Seung, H. ,  YAMAMOTO, Shingo

IPC分类号： C07D473/34 ,  A61K31/522 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00

公开(公告)号：EP3558992A1

公开(公告)日：2019-10-30

申请号：EP17880768.1

申请日：2017-12-14

申请人： ONO Pharmaceutical Co., Ltd. ,  Vanderbilt University

发明人： LINDSLEY, Craig W ,  WIETING, Joshua M ,  MCGOWAN, Kevin M ,  DENTON, Jerod S ,  YASHIRO, Kentaro ,  KURATA, Haruto ,  SEKIOKA, Yoko ,  MORI, Takahiro ,  IWAKI, Yuzo

IPC分类号： C07D471/04 ,  A61K31/277 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/4353 ,  A61K31/4439 ,  A61K31/5375 ,  A61P9/00 ,  A61P29/00 ,  C07C253/30 ,  C07C255/50 ,  C07D257/04 ,  C07D271/06 ,  C07D295/155